Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial

Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial

Purpose Due to advances in anticancer treatment and supportive care, patients increasingly complained about nonphysical side effects of chemotherapy and targeted therapy in recent years. Therefore, continuous assessment of side effects and patients’ perceptions is important. The aim of this study wa...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer Vol. 28; no. 8; pp. 3605 - 3615
Main Authors: Ataseven, Beyhan, Frindte, Johanna, Harter, Philipp, Gebers, Gudrun, Vogt, Caroline, Traut, Alexander, Breit, Elisabeth, Bluni, Vincenzo, Reinisch, Mattea, Heitz, Florian, Kostara, Athina, Kuemmel, Sherko, Prader, Sonia, Bommert, Mareike, Schneider, Stephanie, du Bois, Andreas
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-08-2020
Springer
Springer Nature B.V
Subjects:
Analysis
Breast cancer
Cancer
Cancer therapies
Carboplatin
Care and treatment
Chemotherapy
Medicine
Medicine & Public Health
Nausea
Nursing
Nursing Research
Oncology
Original Article
Ovarian cancer
Pain Medicine
Pertuzumab
Rankings
Rehabilitation Medicine
Sleep disorders
Womens health
Sleep disturbance
Supportive care
Chemotherapy
Targeted therapy
Patients’ perception
Side effect
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Due to advances in anticancer treatment and supportive care, patients increasingly complained about nonphysical side effects of chemotherapy and targeted therapy in recent years. Therefore, continuous assessment of side effects and patients’ perceptions is important. The aim of this study was to evaluate the identification and severity of side effects perceived by ovarian cancer (OC) and breast cancer (BC) patients undergoing contemporary anticancer therapy. Methods Between 2015 and 2017, consecutive chemo-naïve OC and BC patients were enrolled in this prospective cohort study. Interviews were performed 12 ± 3 weeks after start of anticancer therapy, and patients were asked to select and rank, according to severity, 72 physical or nonphysical symptoms potentially related to their treatment. Data were analyzed with descriptive statistics. Results Forty-five OC patients and 98 BC patients completed the interview. Sleeping difficulties were ranked as the most troublesome symptom, followed by concerns about family or partner, and loss of hair. Alopecia was the most predominant side effect for BC patients, whereas OC patients were highly afflicted by numbness in limbs. Chemotherapy alone or in combination with targeted therapy caused pronounced sleep disturbances. Prolonged taxane treatment led to shortness of breath and numbness in limbs. Vomiting was ranked by one and nausea by eight women among the five most bothersome symptoms. Conclusions Sleep disturbances have lately emerged as the most severe problem in women with OC or BC receiving anticancer therapy. Concerns about family and partner were ranked second in the current study and first in previous investigations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-019-05216-y